Scholar Rock Stock Jumps 14% After Official BLA Resubmission for Apitegromab

Scholar Rock Holding Corporation shares surged 14% following the official resubmission of its Biologics License Application (BLA) for apitegromab to the U.S. FDA. The drug is a specialized treatment for Spinal Muscular Atrophy (SMA), addressing a significant unmet medical need. With the filing now complete, a potential FDA decision date has been established for September 2026. This milestone follows extensive regulatory consultations to ensure the submission package meets all necessary technical and clinical requirements. Investors responded positively to the news, viewing the resubmission as a critical step toward the drug's potential commercialization. The company remains focused on navigating the final stages of the regulatory review process to facilitate a successful market launch.